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Abstract
Progressive Multifocal Leukoencephalopathy (PML) is an often fatal disease caused by the reactivation of the JC virus (JCV).
Better understanding of viral-host interactions has been hampered by the lack of an animal model. Engrafting NOD/SCID/IL-
2-Rg (null) mice with human lymphocytes and thymus, we generated a novel animal model for JCV infection. Mice were
inoculated with either a PML isolate, JCV Mad-4, or with JCV CY, found in the kidney and urine of healthy individuals. While
mice remained asymptomatic following inoculation, JCV DNA was occasionally detected in both the blood and the urine
compartments. Mice generated both humoral and cellular immune responses against JCV. Expressions of immune
exhaustion marker, PD-1, on lymphocytes were consistent with response to infection. Using this model we present the first
in vivo demonstration of virological and immunological differences between JCV Mad-4 and CY. This model may prove
valuable for studying JCV host immune responses.
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Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare yet
often fatal disease of the brain for which there is no available
treatment [1]. PML results from lytic destruction of oligodendro-
cytes by JC virus (JCV). While up to 80% of healthy individuals
are seropositive for JCV [2], PML occurs in immunosuppressed
individuals, including those with HIV, malignancies, transplant
recipients, and individuals treated with immunomodulatory
medications. Asymptomatic primary infection of JCV occurs in
childhood and the virus remains detectable in the urine of one
third of healthy individuals without causing any disease [3]. In
patients with PML, active JC viral replication in the brain results
in lysis of oligodendrocytes and consequently demyelination.
Although prognosis is poor for patients with PML, our studies
have demonstrated better survival by those patients with
detectable host cellular immune responses against JCV [4,5,6].
However, JCV-specific T cell responses are low in fresh blood
samples, requiring in vitro stimulation with viral antigen to obtain
robust results [7,8]. Better understanding of host immune
responses and JCV pathogenesis is crucial for developing anti-
viral treatments. Therefore, it is extremely important to develop
an animal model for studying JCV interactions with the immune
system. Unfortunately, JCV, similar to other polyomaviruses, is
highly species-specific and active replication is only permissive in
the human host. Recently, mice engrafted with human fetal stem
cells and thymus, have been employed in the study of other
species-specific viruses [9]. Specifically, the immunodeficient mice,
NOD-SCID/IL-2Rg (null) or NSG, are transplanted with human
fetal bone marrow, liver and thymus (BLT) after sublethal dose of
irradation. After reconstitution with human immune cells, these
mice can generate a full spectrum of human cells including T cells,
B cells, NK cells, macrophages, and dendritic cells. The persistent
residual mouse lymphocytes generally make up less than 5% of
total lymphocytes. Studies have demonstrated immune functions
of these human cells against human-specific viruses including HIV
and EBV [10,11,12]. The prospect of using this humanized mouse
model to study JCV immune response is further enhanced by the
fact that in addition to kidney tubular epithelial cells, the bone
marrow is a site of latency and reactivation for JCV [13].
Therefore, we hypothesize that the engrafted human hematopoi-
etic cells will enable active JCV replication in these mice and
model immune response.
JC viral tropism and virulence is determined in part by the non-
coding hypervariable regulatory region (RR) [14]. While isolates
from urine have a stable non pathogenic RR, known as archetype,
viral strains from the brain or CSF of PML patients contain viral
isolates mostly with rearranged RR due to deletions and
duplications. These were initially isolated at the University of
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be determined whether archetype or the Mad-type of JC virus
causes primary infection in humans. Furthermore, it is not known
if different viral strains elicit different host immune responses. We,
therefore, determined to compare the infection of brain-derived
rearranged isolate, JCV Mad-4, with the urine-derived archetype
isolate, JCV CY, in our humanized BLT mouse model.
Materials and Methods
Humanized BLT mice
Ethics statement. This is study was carried out in accor-
dance with the recommendations in the Guide of the Care and
Use of Laboratory Animals of the National Institute of Health.
The protocol was approved by the Subcommittee on Research
Animal Care of Massachusetts General Hospital (Federal Assur-
ance A3596-01, protocol 2009/N000028/3). All efforts were made
to minimize animal suffering.
Immunodeficient mice, NOD-SCID/IL-2Rg(null) or NSG,
were reconstituted with HLA A0201 –positive human fetal liver
CD34
+ cells and transplanted with autologous fetal thymus and
liver as previously described [10].
JC virus
JCV Mad-4 and JCV CY viral strains were propagated in
astrocytic SVG-A and kidney epithelial COS-7 cells, respectively,
both of which express the SV40 T-antigen. Cells were transfected
with pBJC (Mad-4) and pJC-CY (CY) plasmid DNAs digested to
release the entire JCV genome in linear form. Cells were
subcultured for approximately 3 to 4 weeks until CPE were
observed, then virus was collected from adherent and non-
adherent cells by freeze-thawing and treatment with 0.25%
deoxycholic acid. Virus-containing supernatant was stored at
280uC until needed. Viral titer was determined by qPCR and HA
assay as described previously [16,17]. Each virus was injected
intraperitoneally at a dose of 2,500 HAU (equivalent to 2.5610
7
viral copies) or 5,000 HAU (equivalent to 5610
7 viral copies) per
mouse for both viruses.
Extraction of viral nucleic acids and detection with
quantitative PCR (qPCR)
DNA. The Qiagen MinElute kit (Qiagen, CA) was used
following the manufacturer’s instructions for DNA extraction from
urine and plasma. The Qiagen Blood kit was used following the
manufacturer’s instructions for DNA extraction from whole blood.
Because of the variable volume of blood and urine samples
obtained from each animal, viral DNA were first extracted from
the samples. An aliquot was used for determination of total DNA
concentration. The results of JC viral load were expressed per mg
of extracted DNA, rather than per ml of the sample. Qiagen
Tissue kit was used for DNA extraction of organs. QPCR was used
to detect and quantify JCV DNA in all samples as previously
described [18]. The standard curve ranges from 1 copy to 10
6
copies per sample well. Results above 1 copy are considered
positive.
RNA. Total RNA was extracted using RNeasy Mini kit
(Qiagen, CA) and reverse transcribed using RNA-to-cDNA kit
(Applied Biosystems). Real-time PCR was performed on compli-
mentary DNA using TaqMan Gene Expression master mix
(Applied Biosytems). Reactions were performed in 50 mli n
triplicate on a 7300 Real Time PCR system (Applied Biosystems).
Measuring anti-JCV antibodies in serum
A virus-like particle-based ELISA was used to detect IgM and
IgG antibodies to JCV capsid as previously described [19].
Lymphocyte phenotyping
Direct immunofluorescence staining of whole blood was
performed using mouse CD45 (eBiosciences; clone 30-F11),
human CD45 (Invitrogen; clone H130), CD3 (BD Bioscience;
clone SP34-2), CD4 (Invitrogen; clone S3.5), CD8 (BD Bioscience;
clone RPA-T8), CD19 (BD Bioscience; clone SJ25C1), and PD-1
(BioLegend; clone EH12.2H7) for 25 minutes at 4uC. RBC’s were
lysed by treatment with BD FACS Lysing Solution for 10 minutes
at 4uC. Cells were washed twice with PBS containing 2% FBS.
Analysis was performed on a LSRII flow cytometer (BD
Biosciences) and FlowJo software (Treestar Inc.).
Generation of human B lymphoblastoid cell line (BLCL)
EBV-transformed autologous B-lymphoblastoid cell line (BLCL)
was generated by incubating 2610
7 PBMC in B95.8 supernatant,
an EBV infected marmoset cell line, at 37uC for 3 hours,
resuspended (1610
6 cells/ml) in RPMI 1640 containing 20%
FBS and 1 mg/ml cyclosporine, and plated in 48-well plates. After
7 days, cells were fed with RPMI 1640 containing 12% FBS every
2–3 days and monitored for signs of immortalization. After
immortalization, BLCL were used as feeder cells for the ELISpot
assay.
Isolation of Splenocytes
Spleens from individual mice were removed, placed in RPMI
1640 with 12% FBS, and disrupted by passage through a 70 mm
filter. RBCs were lysed by using ACK solution. Cells were washed,
counted, and resuspended (3–3.5610
6 cells/ml) in RPMI 1640
containing 12% FBS. 7610
6 cells per well were cultured in a 12-
well plate with each peptide pool. The JCV VP1 peptide pools
comprised of 15 amino acids(aa) peptides overlapping by 11-aa
and encompassed the entire VP1 protein including amino acid
variations in both JCV Mad and CY types of viruses. Additionally,
3.5610
6 cells were stimulated with HLA-A*0201-restricted JCV
VP1 epitopes, VP1p36 or VP1p100, for tetramer staining. 72 hours
later recombinant human IL-2 (50 U/ml) was added to each
sample. After 10 days of in vitro stimulation, splenocytes were used
to assess JCV specific cellular immune responses.
Elispot
Prior to ELISpot assay, BLCL (2610
6 cells/ml) were incubated
with each peptide pool for 16 hours. After incubation, BLCL were
treated with mitomycin C (0.5 mg/ml) for 2.5 hour, washed twice
and resuspended at 1610
6 cells/ml. After pretreatment, 5610
4
BLCL were co-cultured with 5610
4 splenocytes on 96-well
MultiScreen HTS plates (Millipore) previously coated with anti-
human IFN-c at 5 mg/ml and stimulated with the same peptide
pool as used for stimulation at beginning of culture. Each test
sample was run in triplicate. After 36 hour incubation at 37uC,
plates were washed, incubated with anti-human IFN-c biotin
(Biosource) for 2 hours at room temperature, washed, and
incubated with streptavidin (Southern Biotechnology). The Plates
were developed with nitroblue tetrazolium-5-bromo-4-chloro-3-
indolylphosphate chromogen (Pierce) and analyzed on an Im-
munospot Analyzer (Cellular Technology Limited). An ELISpot
result was considered positive when the numbers of spot forming
units (SFU) were greater than three times the baseline value, and
when the number of SFU is greater than 50 per 10
6 cells after
JCV Immune Responses in a Humanized Mouse Model
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baseline values.
Intracellular Cytokine Staining
1610
6 splenocytes were incubated in RPMI 1640 with 12%
FBS medium alone (unstimulated), with a peptide pool of the VP1
peptide (2 mg/ml), or with PMA and ionomycin (1 mg/ml and
5 mg/ml, respectively) at 37uC for 6 hours. All samples received
monensin (GolgiStop; BD Bioscience) after the first hour of the
incubation. Following incubation, cells were stained with fluores-
cently conjugated antibodies specific for mouse CD45 (eBios-
ciences; clone 30-F11) and for human CD45 (Invitrogen; clone
HI30), CD4 (Invitrogen; clone S3.5), CD8 (BD Bioscience; clone
RPA-T8), PD-1 (BioLegend; clone EH12.2H7), and an amine dye
(Invitrogen) for live/dead cell discrimination. After fixation and
permeabilization (BD Cytofix/Cytoperm), cells were stained with
antibodies specific for IFN-c (BD Bioscience; clone B27) and CD3
(BD Bioscience; clone SP34-2. Data were acquired on a LSRII
flow cytometer (BD Biosciences) and analyzed with FlowJo
software (Treestar Inc.).
In some experiments, splenocytes were cultured with JCV
capsid protein VP1 peptides for 12 days and then stimulated with
the same peptides for a second time for ICS. Negative control
consisted of splenocytes with no peptide stimulation and positive
control consisted of splenocytes stimulated with PMA. In addition,
a group of splenocytes were cultured in the presence of JCV
peptides but not restimulated with peptides during ICS. The IFN-
c secretions of these cells measured during the ICS were
considered the baseline IFN-c expressions. ICS result was
considered positive when the percentage of IFN-c producing
CD4
+ or CD8
+ T cells were equal to or greater than two times the
baseline value. The ICS results were reported after subtraction of
baseline value as previously reported [20].
Tetramer Staining
1610
6 splenocytes previously stimulated with the HLA-A*0201-
restricted JCV VP1 epitopes, VP1p36 or VP1p100, were stained
with a fluorescently conjugated tetramer specific to HLA-A*0201/
VP1p36 or HLA-A*0201/VP1p100 for 30 minutes at room
temperature and followed immediately by direct staining with
antibodies specific for mouse CD45 and for human CD3, CD4,
CD8, and CD45 for 25 minutes at 4uC. Prior to staining with
tetramer, each sample was stained with an amine dye (Invitrogen)
for live/dead cell discrimination. Data were acquired on a LSRII
flow cytometer (BD Biosciences) and analyzed with FlowJo
software (Treestar Inc.).
Immunohistochemistry
Mice kidneys were extracted and fixed in 4% paraformaldehyde
overnight, then placed in PBS containing 30% sucrose overnight,
and finally frozen in OCT compound (Tissue tek, Sakura).
Immunoperoxidase staining of anti-JCV antibody VP1 PAB597 (a
generous gift from Walter Atwood) on 5 mm serial sections was
performed using the Vectastain Elite ABC kit (Vector Labs)
following manufacture’s recommendations, and developed with
DAB chromogen (Vector Labs), as previously described [21].
Sections were counter stained with Mayer’s hematoxylin.
Results
Infection of humanized BLT mice with JCV
Similar to asymptomatic human infection with JCV, the
humanized BLT mice in the experiments did not demonstrate
any symptoms with exposure to JCV. Their body weights and
appearances were monitored and did not differ from the
phosphate buffered saline (PBS)-injected control group. Some of
the mice in both study groups and in the uninfected control group
suffered from graft versus host disease with symptoms of alopecia
and weight loss, requiring euthanasia prior to the planned study
points. However, there were no significant differences in the
survival between the two virus-inoculated groups and the PBS-
injected control group when analyzed using the Kaplan-Meier
survival analysis (data not shown).
Detection of JCV DNA in urine of humanized BLT mice
To address whether humanized BLT mice inoculated with JCV
can shed virus in the urine, we intraperitoneally injected 2,500
HAU (equivalent to 2.5610
7 viral genomes) [17] of JCV CY in 5
mice, 2,500 HAU of JCV Mad-4 in 5 mice, and 500 ml of PBS in 5
mice as negative control. We mapped the urine detection of JCV
by quantitative PCR (qPCR) in urine samples collected on days 7,
22, 35, 49, 77, 91, and 104 after inoculation (Figure 1A). In total,
2 of 5 (40%) JCV CY-inoculated mice (CY mice) and 3 of 5 (60%)
of JCV Mad-4-inoculated mice (Mad-4 mice) had detectable JCV
DNA in the urine on at least one time point. In the CY mice, JCV
DNA was detected in 2 mice as early as day 7. JCV DNA became
undetectable in the urine of both of these mice until one had a
second detection on day 35 and the other on day 77. The quantity
of JCV DNA detected in urine of CY mice ranged from 13 to 86
copies per microgram of DNA. The first detection of JCV DNA in
Mad-4 mice occurred in one mouse on day 77. This mouse and a
second one had urine with detectable JCV DNA on day 91, and
finally a third mouse had positive urine detection on day 104. The
quantity of JCV DNA detected in urine of Mad-4 mice ranged
from 11 to 156 copies per microgram of DNA. JCV DNA was not
detected in urine from any PBS-injected control mice (PBS mice).
Presence of JCV DNA in the urine of the humanized BLT
mouse inoculated with JCV parallels that of JCV infection in
humans where viral shedding occurs in approximately one third of
healthy asymptomatic individuals [3]. Furthermore, while viral
shedding occurred in some mice on multiple occasions, no mouse
was a constant shedder.
Detection of JCV nucleic acids in blood of humanized BLT
mice
To examine the presence of JCV DNA in the blood of
humanized BLT mice, we sampled mice blood on days 24, 44, 65,
86, and 106 after inoculation. Altogether, 1 of 5 (20%) CY mice
and 3 of 5 (60%) Mad-4 mice had detectable JCV DNA on at least
one time point during the study (Figure 1B). JCV DNA was
detected in one CY mouse on day 106 with 70 copies of JCV DNA
per mg of DNA tested. JCV DNA was detected in one Mad-4
mouse on day 44, and again in the same mouse on day 106. A
second Mad-4 mouse had detectable JCV DNA in blood on day
86, and a third one had detectable DNA on day 86 as well as on
day 106 (Figure 1B). The quantity of JCV DNA detected in
blood of Mad-4 mice ranged from 226 to 1730 copies per mgo f
DNA. Detection of JCV RNA was negative in all blood samples.
No JCV DNA or RNA was detected in the blood of PBS mice.
While the detection of JCV DNA in the urine did not always
correlate with detection of JCV DNA in the blood in the same
mouse, some of the mice had detectable DNA in both
compartments. In the CY mice, one of the two mice with
detectable JCV DNA in urine early on day 7 also had detectable
JCV DNA in the blood on day 106. In the Mad-4 mice, 3 mice
had detectable JCV DNA in urine. Two of these mice had positive
detection of JCV DNA in the blood.
JCV Immune Responses in a Humanized Mouse Model
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viral DNA can be occasionally detected in urine and peripheral
blood [22]. While the mice with detectable JCV DNA in the urine
did not always have detectable JCV DNA in the blood, the
detection of viral DNA in both compartments in some of the mice
may indicate increased viral replication or decreased immune
function in these mice.
Detection of anti-JCV antibodies in humanized BLT mice
infected with JCV
Anti-JCV IgM and IgG were not detectable in mice inoculated
with 2,500 HAU of the viruses on days 14–120 after infection.
However, in mice inoculated with 5,000 HAU of the viruses, IgM
seroconversion was detected in 4 of 13 (31%) tested mice, or 4 of
32 (12.5%) samples in the CY mice; and 7 of 16 (44%) mice, or 10
of 40 (25%) samples in the Mad-4 mice (Figure 2). One of 14 CY
mice and 1 of 16 Mad-4 mice had only one serum available. The
rest of the mice had 2 to 3 serum samples from different dates
available for detection of anti-JCV IgM and IgG. In the CY mice,
none of the 14 mice had detectable anti-JCV IgM on day 19. Four
of the 14 mice showed IgM seroconversion on days 42, 47, 64, and
90. In the Mad-4 mice, none of the 13 mice tested had detectable
anti-JCV IgM on day 19 after inoculation. Two of the 16 mice
displayed IgM seroconversion on day 47, and one became IgM
positive on day 56. Four other mice had IgM seroconversion on
day 67, and 3 of these remained IgM positive when measured
again on days 75, 78, and 103. The quantity of anti-JCV IgM in
JCV Mad-4 group (median 0.127, range 0.039–0.418) was
significantly higher than that of the JCV CY group (median
0.042, range 0.039–0.046), (p=0.03, Mann-Whitney test).
Anti-JCV IgG was not detected in any of the animals. These
serology data show that JCV-inoculated humanized BLT mice
have functional human B cells that produced measurable levels of
anti-JCV IgM antibodies.
Detection of JCV-specific cellular immune response in
humanized BLT mice inoculated with JCV
Intracellular cytokine staining (ICS) for IFN-c expression on
both CD4
+ and CD8
+ T-lymphocytes, as well as tetramer staining
for JCV-specific CD8
+ T lymphocytes and ELISpot assays were
performed using splenocytes to assess cellular immune responses
against JCV in BLT mice reconstituted with HLA A*0201 positive
fetal tissues. We first performed ICS with splenocytes from JCV-
inoculated mice and demonstrated positive but low levels of IFN-c
expression on both CD4
+ and CD8
+ T cells in 3 out 4 Mad-4 mice
(CD4: mean 0.003%, range 0–0.044% and CD8: mean 0.004%,
range 0–0.027%) and in 4 out of 4 CY mice (CD4: mean 0.008%,
range 0–0.045% and CD8: mean 0.012%, range 0–0.15%) 6
weeks after inoculation. A representative result is shown in
Figure 3A. These low level responses are similar to those obtained
in humans ex vivo [7,8]. To ascertain these results, we then cultured
splenocytes with JCV VP1 pooled overlapping peptides for 12 days
prior to performing immune assays. A representative example of
an ICS result is shown in Figure 3B and a tetramer staining result
in Figure 3C. In the CY mice, 3 of 11 (27%) mice demonstrated
detectable cellular immune responses with initial infection. ICS
was positive in both CD4
+ (mean: 1.1% and range 0.41–2.32%)
and CD8
+ (mean: 1.6% and range 0.41–3.73%) T cells in two
different mice on day 42 and day 47 after inoculation. A third
mouse had detectable JCV-specific T cells by tetramer staining on
day 96.
In the Mad-4 mice, 4 of 14 (29%) mice had detectable cellular
immune response to JCV with initial inoculation. One mouse
demonstrated response on day 47 with detectable IFN-c expres-
sion in both CD4
+ and CD8
+ T cells by ICS. A second mouse also
had positive ICS detections in both CD4
+ and CD8
+ T cells as
Figure 1. Detection of JCV DNA in the urine and blood of JCV
inoculated humanized BLT mice. Only positive data are shown. (A)
Urine samples were collected day 7, 22, 35, 49, 77, 91, and 104 post
inoculation. JCV CY inoculation resulted in an early detection of JCV
DNA in the urine on day 7 compared to first detection of JCV Mad-4 in
the urine on day 77. (B) Blood samples were collected 24, 44, 65, 86, and
106 days post inoculation. Inoculation with JCV Mad-4 resulted in more
frequent detection of JCV DNA in the blood compared to JCV CY.
Unique symbols are used for individual mice; CY: JCV CY; Mad-4: JCV
Mad-4.
doi:10.1371/journal.pone.0064313.g001
Figure 2. Humoral immune responses in JCV-inoculated
humanized BLT mice. Anti-JCV IgM were detected 42–103 days post
inoculation. JCV Mad-4 inoculation elicited a stronger humoral immune
response than JCV CY inoculation. Quantitative IgM values are
expressed on a logarithmic scale. Dashed line: cut-off for positive
values (OD450 nm=0.039).
doi:10.1371/journal.pone.0064313.g002
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6 cells,
background 20) on day 91. On day 96, a third mouse had
detectable JCV-specific T cells by tetramer staining as well as
positive ELISpot assay (760 SFU per 1610
6 cells, background
180), and finally a fourth mouse had detectable IFN-c expression
in CD4
+ T cells by ICS on day 103. The IFN-c expression in
Figure 3. Humanized BLT mice inoculated with JCV displayed cellular immune responses against JCV VP1 antigens. (A) Intracellular
staining (ICS) of splenocytes detected an increased IFN-c expression on both CD4
+ and CD8
+ T cells, after stimulation with JCV peptides. (B) Culturing
splenocytes with JCV capsid protein VP1 peptide pools for 12 days and then stimulated with the peptide pool a second time for ICS increased IFN-c
expression on both CD4
+ and CD8
+ T cells in a mouse inoculated with Mad-4, but not in a PBS-injected mouse. (C) Tetramer staining detected JCV
VP1 epitope-specific CD8
+ T cells after stimulation with A*0201-restricted JCV VP1 p100 peptide in mice inoculated with either JCV Mad-4 or CY, but
not in a PBS-injected mouse. Percentages of positive cells are indicated.
doi:10.1371/journal.pone.0064313.g003
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+ T cells by ICS had a mean of 0.60% (range: 0.24–1.36%);
and on CD8
+ T cells the mean was 0.83% (range: 0.51–1.18%).
To test whether additional exposure with the same virus can
boost cellular immune response we reinoculated two CY and two
Mad-4 mice on day 97 after initial inoculation with the same dose
and types of virus. One mouse was assayed 40 hours after
reinoculation and a second 6 days after reinoculation. In the CY
mice, neither demonstrated detectable cellular immune response
against JCV. In the Mad-4 mice, the first mouse sacrificed
40 hours after reinoculation showed detectable responses by both
ICS (CD4
+ T-cells: 0.26% and CD8
+ T cells: 0.95%) and ELISpot
(250 SFU per 1610
6 cells, background 60). The second mouse,
sacrificed 6 days after reinoculation, showed detectable responses
in ICS (CD4
+ T cells: 1.58% and CD8
+ T cells: 1.32%).
In the Mad-4 mice, there were significantly more mice with a
positive cellular immune response against JCV that had detectable
JCV DNA in the blood as compare to mice without cellular
immune response (4/6 vs 1/10, p=0.04, Fisher’s Exact test).
These data demonstrate that a subset of humanized BLT mice
inoculated with JCV are able to mount a cellular immune response
against JCV, as is the case in humans. Presence of JCV DNA in
the blood increased the likelihood of detection of a cellular
immune response against JCV in the Mad-4 mice. The immune
responses data are summarized in Table 1.
Analysis of T-lymphocytes exhaustion in JCV infected
humanized BLT mice
We examined the immune exhaustion marker, programmed cell
death (PD-1), expression in humanized BLT mice inoculated with
JCV CY and Mad-4. Six weeks after inoculation, both the CY and
Mad-4 mice had significant increase in PD-1 expressions on CD4
+
T cells, compared to the PBS mice (p=0.02 and ,0.0001)
(Figure 4A). This increase was also observed in the CD8
+ T cells
when comparing both the CY and Mad 4 mice to the PBS mice
(p=0.01 and 0.002) (Figure 4B). We have previously shown that,
PD-1 was elevated on both CD4
+ T cells and CD8
+JCV-specific T
cells in patients with PML [23]. The up regulation of PD-1 in the
virus-inoculated mice suggests that JCV infection may have a
similar effect on immune exhaustion in the mouse model.
Detection of JCV in kidney of humanized BLT mice
To determine JC viral tissue tropism in this model, we analyzed
the organs of JCV-inoculated humanized BLT mice for the
presence of JCV DNA. While no JCV DNA was detected in tissues
from brain, intestine, liver, lung, lymph nodes, or bone marrow,
we consistently detected JCV DNA in the kidney of Mad-4 mice.
In humanized BLT mice inoculated with 2,500 HAU of either
JCV Mad-4 or CY virus, JCV DNA was detected in 4 of 9 (44%)
Mad-4 mice and in none of the CY mice 120 days after
inoculation. In humanized BLT mice inoculated with 5,000 HAU
of either JCV Mad-4 or CY virus, JCV DNA was detected in the
kidney from 9 of 16 (56%) Mad-4 mice and in 7 of 12 (58%) CY
mice, harvested days 42 to 103 after inoculation. Kidney tissues
from PBS mice did not have detectable JCV DNA. The quantities
of JCV DNA in the kidney tissues were determined by qPCR and
were all below 500 copies/mg of DNA. As a confirmatory
experiment, we amplified, cloned, and sequenced the JCV RR
from the kidneys of multiple Mad-4 mice. Sequencing results
confirmed that the RR is same as the JCV Mad-4 virus used for
inoculation (data not shown). Furthermore, we performed
immunohistochemistry staining and detected rare kidney tubular
cells containing JCV VP1 protein in JCV Mad-4-inoculated mice
(Figure 5).
Discussion
Our pilot data demonstrate that the humanized BLT mouse
may be useful for the study of immune response against JCV.
Similar to humans, primary infection with JCV did not elicit any
specific symptoms. Since infection with JCV is asymptomatic, it is
difficult to calculate the optimal dose of viral inoculum. While
mice inoculated with 2,500 HAU of either JCV Mad-4 or CY did
not produce detectable anti-JCV IgM or IgG within 120 days after
initial inoculation, IgM seroconversion was detected in 29% of CY
and 44% of Mad-4 mice inoculated with 5,000 HAU of the virus.
The absence of IgG may be caused by the fact that the
reconstituted immune system in this model is immature and
longer exposure to virus is necessary to trigger IgG production, as
seen with HIV [10]. Thus, this BLT mouse model may more
accurately depict JCV immune response by human fetus.
Furthermore, we injected JCV intraperitoneally based on our
experience that intraperitoneal injection of HIV achieved similar
viral infection as intravenous injection in BLT mice. However, this
may be different for JCV. Thus, higher quantities, longer exposure
to JCV, and intravenous injection can be tested in future
experiments to elicit possibly stronger immune responses.
JCV was occasionally detected in the blood of virus-inoculated
humanized BLT mice. Similar to human infection, JCV is
occasionally detected in the blood in 20–60% of the mouse
samples, up to 106 days post inoculation, suggesting persistent low
level viral replication. Alternatively, JCV DNA detections may
result from residual inoculums; this possibility is unlikely due to the
elapsed time post inoculation. While JCV DNA is usually not
detected in the peripheral blood of healthy individuals, it was
detected in 13% of PBMC and in 22% of plasma from HIV
positive individuals without PML [22]. The detection of JCV
DNA in the plasma of these mice may be due to incomplete
immune control of JCV and perhaps indicate that the mice
immune system is more comparable to those of humans with
immunosuppressions.
JCV was detected in the urine of virus-inoculated mice at a
frequency of 40%–60% during the course of our experiments as
compared to detection in one third of healthy adults as well as
immunosuppressed patients with or without PML. JCV CY virus
was detected in the urine as early as 7 days after infection, prior to
detection in the plasma and prior to the detection of JCV Mad-4
virus. This may indicate that JCV CY is preferentially processed
through the renal system. While it is not known if JCV CY or
Mad-type of virus is responsible for primary infection in humans,
JCV CY is the predominant virus detected in urine and in kidneys
in both healthy individuals as well as PML patients. Therefore,
these data provide further evidence that the presence of JCV in the
renal system may be partially determined by the regulatory region
of the virus. The exact mechanisms of regulatory region exerting
influence on this selection need to be further investigated.
Similar to other polyomaviruses, JCV is species-specific and can
only replicate in humans. However, while the humanized BLT
mice in our experiments had no human kidney tissues, JCV DNA
and protein were detected in the mouse kidney tissues as late as
103 days after inoculation. It is possible that mouse kidney
epithelial cells express receptors similar to those in humans,
facilitating JC virus entry. Further investigation is needed to
characterize the viral entry and determine whether JCV enters the
kidneys as free virus or attached to cells such as lymphocytes. Once
inside the kidney epithelial cells, it is unclear if mice cellular
machinery can support JCV replication though previous studies
suggest that the rodent cellular machinery would not support
productive infection [24]. The detection of JCV in the urine could
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of viral DNA into the lumen of the tubules after death of the
kidney epithelial cells. While about half of the kidneys contained
detectable JCV DNA, fewer urine samples contained JCV DNA.
This may indicate that JCV can be latent in the kidney of BLT
mice without active replication and release into the urine. The
detection in urine increased with increased dose of inoculated
JCV. Therefore, a higher JCV inoculum may further increase
urine detection of JCV in this model.
We and others have previously studied cellular immune
responses to JCV in humans and showed that the major limitation
to immune response assays is the low frequency of detectable JCV
specific T-cells in peripheral blood ex vivo [7,8]. Therefore, to
better characterize the JCV-specific cellular immune response and
to compare with human JCV immune responses, we performed
ICS, tetramer staining, and ELISpot after stimulation of mice
splenocytes with JCV peptides in vitro, similar to our previous
experimental methods with human blood samples [20]. To control
for the culturing conditions, we have developed stringent criteria
to evaluate assay results in order to account for false positives that
may have risen from in vitro experimentation. The magnitude of
the immune responses measured in our model is comparable to
those seen in healthy individuals. However, humoral or cellular
immune responses were detected only in a subgroup of mice in our
study. This may be due to several factors. First, we performed
immune assays starting day 42 after inoculation. Therefore, some
mice may have generated earlier responses which were no longer
detectable at that time point. Second, although the JCV was latent
in the kidneys, the lack of robust active viral replication may have
also reduced the immune response over the long term.
Transplanting human kidney tissues in these BLT mice may
provide a source for constant JC viral replication and increase
Table 1. Detection of anti-JCV immune response in JCV-inoculated humanized mouse.
Days post
infection at
Sacrifice Serology ICS Tetramer ELISpot
Virus ID# IgM CD4 CD8
JCV CY 14 2 ++ + 22
24 7 2 ++ 22
34 7 + 22 2 2
4 53 N/A N/A N/A N/A N/A
55 6 22 2 2N/A
65 6 22 2 2N/A
76 1 22 2 22
86 4 + 22 2 2
96 4 22 2 22
10 90 + 22 2 2
11 96 22 2 + 2
12 96 22 2 22
13
A 99 22 2 22
14
B 103 22 2 22
JCV Mad-4 15 47 + 22 2 2
16 47 22 2 22
17 47 ++ + 22
18 56 22 2 2N/A
19 56 + 22 2 2
20 56 22 2 2N/A
21 64 22 2 22
22 70 22 2 22
23 75 + 22 2 2
24 78 + 22 2 2
25 91 2 ++ 2 +
26
A 94 2 ++ 2 +
27 96 2
C 22 ++
28 96 22 2 22
29 103 ++ 22 2
30
B 103 2 ++ 22
AMouse reinoculated with virus then sacrificed 40 hours after reinoculation.
BMouse reinoculated with virus then sacrificed 6 days after reinoculation.
CIgM detected on day 67, but reverted to negative at sacrifice 96 days after inoculation.
doi:10.1371/journal.pone.0064313.t001
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also elicit increased magnitudes of response in a larger number of
animals. Future efforts should be directed toward boosting this
immune response. Lastly, while human immune responses to JCV
are well studied in adults, little is known of the magnitude or
dynamics of JCV-specific immune responses in primary infection,
which may be represented by this model.
Our data suggest several virological differences between JCV
CY and Mad-4. Humanized BLT mice inoculated with JCV CY
and Mad-4 virus showed differences in viral DNA load and the
magnitude of the immune response. This may be due to several
factors. First, while the same dose of JCV CY and Mad-4 were
given to the mice, JCV CY may have a slower rate of viral
replication in the humanized BLT mice, resulting in quantitatively
fewer antigens. Our finding that JCV DNA was detected at a
higher frequency in the blood of Mad-4 mice as compared to CY
mice (60% vs. 20%) also supports this argument. Second, these
two viruses may have different interactions with the host immune
cells. In addition, mice infected with JCV Mad-4 produced
significantly more anti-JCV IgM antibodies than mice infected
with JCV CY. Lastly, JCV CY and Mad-4 may induce different
immune memory and rate of response. Whereas the cellular
immune response in Mad-4 mice is correlated with the detection of
JCV DNA in peripheral blood, this was not seen in CY mice. The
immune response differences are further demonstrated by
reinoculation of two mice from each group. While both of the
Mad-4 reinoculated mice showed detectable cellular immune
responses, this was not the case with the CY reinoculated mice.
These differences in both humoral and cellular immune responses
to these two viruses argue against a mere reaction to the initial
viral inoculums and suggest a low level active infection.
Elucidation of JC virology is necessary in order to better
understand JCV pathogenesis and PML. These results are the first
in vivo demonstration of distinct virological and immunological
differences between JCV Mad-4 and CY. The quantitative
differences in DNA viral load detected in blood and urine may
be due to different replication efficiency associated with sequence
differences in the non-coding RR of these viruses. These
differences in the RR can alter the binding of nuclear transcription
factors. The host immune response differences may be due to the
amino acid differences between JCV CY and Mad-4. These viral
strains have a total of 17 amino acid differences in the six JCV
proteins, including seven located in the capsid proteins VP1, -2
and -3. Amino acid changes in the VP1 protein have been
described in JCV strains isolated from the brains of PML patients
compared to those found in the urine of healthy people [25,26,27].
Further studies using the humanized BLT mouse model will be
needed to determine the role of the immune response in the
differential containment of JCV Mad-4 and CY.
Although the detected levels of JC viral DNA and JCV-specific
immune responses are low in our study, our data suggests that a
subgroup of the JCV-inoculated mice were indeed infected with
the virus. First, we were able to detect JCV DNA in the urine and
blood of some inoculated mice as late as 104 days after
inoculation. Second, in a subgroup of the virus-inoculated mice,
we demonstrate positive cellular and humoral immune responses
using the stringent criteria used for human responses. Lastly, the
lymphocyte exhaustion marker, PD-1, associated with JCV
infection in humans, is also elevated on both CD4
+ and CD8
+
T cells in virus-inoculated mice.
While our humanized BLT mouse model does not recapitulate
the disease PML, our data showed that this model may be useful in
studying the immune response of a human-specific virus, such as
JCV. Using humanized BLT mice, we have demonstrated positive
cellular and humoral immune responses, albeit at low levels. Better
understanding of viral interactions with host immune response is
crucially needed to prevent PML in immunosuppressed patients.
Figure 4. JCV-inoculated humanized BLT mice showed in-
creased expression of the cell exhaustion marker, PD-1, on
splenocytes. PD-1 expression was measured on splenocytes after
stimulation with JCV VP1 peptide pools. A significantly higher
percentage of CD4
+ and CD8
+ T cells expressed PD-1 in either the
JCV Mad-4 or CY mice as compared to the PBS mice. Bars illustrate the
means and standard deviation above the means in each group.
doi:10.1371/journal.pone.0064313.g004
Figure 5. JCV-inoculated humanized BLT mice showed rare
detection of JCV VP1 protein in the kidney. Immunohistochem-
istry staining of JCV VP1 protein was not detected in the kidney of PBS-
inoculated mice (A), but was detected in rare kidney cells in JCV Mad-4
inoculated mice (B). The images are magnified 40-fold, and the inset is
magnified 100-fold. Scale bar=100 mm.
doi:10.1371/journal.pone.0064313.g005
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PLOS ONE | www.plosone.org 8 May 2013 | Volume 8 | Issue 5 | e64313The current lack of an animal model greatly hampers JCV
research. Therefore, this humanized BLT mouse model can be
utilized in future studies in deciphering the immune response in
JCV and HIV co infection, and chemical immunosuppression with
monoclonal antibodies.
Conclusions
The humanized BLT mice provide a possible animal model of
human immune response to JCV. The human lymphocytes
engrafted in the mouse model generated both humoral and
cellular responses against JCV. Furthermore, we have demon-
strated distinct virological and immunological differences between
JCV CY and JCV Mad-4. This model may prove very valuable for
studying JCV host immune responses and aid in elucidating
alterations caused by immuno modulations, and devise better
therapeutic interventions.
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